RecruitingEarly Phase 1NCT06104215

BGT007H Cells for the Treatment of Refractory Digestive System Tumors

Clinical Study on the Safety and Initial Efficacy of BGT007H Cell Therapy in Patients With Recurrent/Metastatic Refractory Digestive Tract Tumors

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Enrollment

14 participants

Start Date

Oct 22, 2023

Study Type

INTERVENTIONAL

Conditions

Digestive Tract Cancer

Summary

This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007H injection in the treatment of recurrent/metastatic/refractory digestive system tumors.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called BGT007H Injection for people with digestive tract cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBGT007H Injection

BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10\^8 cells,5.0 ×10\^8 cells, 1.0× 10\^9 cells,3.0 × 10\^9 cells,6.0 ×10\^9 cells.

Locations(1)

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06104215